Midwest Chest Consultants, PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$188,338	21
2024	Research	$475,123	20
2023	Research	$164,384	33
2022	Research	$165,344	35
2021	Research	$268,728	38
2020	Research	$103,942	6

Breakdown

Who paid Research payments · program years 2020–2025

Sanofi US Services Inc. $654,003 118 payments
AstraZeneca Pharmaceuticals LP $646,612 22 payments
AstraZeneca UK Limited $42,671 3 payments
Cipla USA Inc. $22,534 9 payments
Novartis Pharmaceuticals Corporation $39 1 payment

Studies the money was for Research payments · program years 2020–2025

Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $568,625 90 payments
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease $279,093 2 payments
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) $97,679 3 payments
A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ) as a Tool that Identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma $76,219 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $58,035 22 payments
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $50,192 7 payments
Onset of Effect Questionnaire $45,509 3 payments
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL $43,496 1 payment
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA $40,196 2 payments
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma $26,890 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.